- Stock: Pre-Order
- Brand: Novo Nordisk
- Product ID: Protamine Crystallised Insulin Aspart
100% Secure Payment
bKash | Nagad | Cards via SSLCommerz | COD
Monthly Medicines Available | Free Delivery on Eligible Orders
This Item is for pre order
NovoRapid Penfill – Insulin Aspart 100 IU/ml Cartridge by Novo Nordisk
| Generic Name | Insulin Aspart |
| Brand Name | NovoRapid Penfill |
| Manufacturer | Novo Nordisk A/S (Denmark) |
| Dosage Form | Solution for Injection — 3 ml Penfill Cartridge |
| Strength | 100 IU/ml (U-100) |
| Pack Size | 5 Penfill cartridges × 3 ml = 1,500 IU total |
| Drug Class | Rapid-acting Insulin Analogue (Mealtime Insulin) |
| Prescription Required | Yes — Rx Only |
| Onset / Peak / Duration | Onset: 10–20 min | Peak: 1–3 hrs | Duration: 3–5 hrs |
What is NovoRapid Penfill?
NovoRapid Penfill contains insulin aspart 100 IU/ml — the same rapid-acting formulation as the NovoRapid FlexPen — in a 3 ml Penfill cartridge for compatible NovoPen reusable devices (NovoPen 4, 5, Echo). Preferred by patients using reusable pens for sustainability or needing the NovoPen Echo's dose memory function. Each 3 ml cartridge holds 300 IU. Onset within 10–20 minutes, peak 1–3 hours, duration 3–5 hours — closely mimicking the body's natural post-meal insulin response.
Generic Name & Composition
Each ml contains 100 IU of insulin aspart (rDNA origin). Insulin aspart has a single B28 substitution (proline → aspartate) preventing hexamer self-association and enabling rapid monomeric absorption. Identical formulation to NovoRapid FlexPen — only the delivery format differs. Not for use in syringes; only in Penfill-compatible pen devices.
Indications
- Type 1 diabetes — bolus (mealtime) component in basal-bolus regimen
- Type 2 diabetes — mealtime insulin when oral therapy is insufficient
- CSII pump therapy — aspart is approved for continuous subcutaneous infusion
- Patients preferring NovoPen reusable devices (NovoPen 4, 5, Echo)
How It Works — Mechanism of Action
After subcutaneous injection via compatible pen device, insulin aspart's rapid monomeric absorption activates insulin receptors within 10–20 minutes. Stimulates GLUT-4 mediated glucose uptake in muscle and adipose tissue, suppresses hepatic glucose output, promotes glycogen synthesis — directly counteracting the post-meal blood glucose rise. Peak at 1–3 hours aligns with post-prandial glucose peak.
Dosage & Administration
Timing: 0–15 minutes before meals (or immediately after if meal size uncertain). Dose: Individualised — 4–15 IU per meal. Device: Load Penfill into NovoPen 4, 5, or Echo. Prime 2 IU. Dial dose, inject subcutaneously, hold 6 seconds. Rotate sites (abdomen, thigh, upper arm).
Side Effects
Very common: Hypoglycaemia — principal risk of mealtime insulin.
Common: Injection site reactions, lipohypertrophy from poor rotation.
Uncommon: Lipoatrophy, peripheral oedema, transient visual changes at initiation.
Rare: Anaphylaxis, severe allergic reactions.
Drug Interactions
Increase hypoglycaemia: Sulphonylureas, GLP-1 agonists, SGLT-2 inhibitors, ACE inhibitors, MAO inhibitors, salicylates, alcohol.
Reduce effect: Corticosteroids, glucagon, thyroid hormones, thiazides, sympathomimetics.
Caution: Beta-blockers mask hypoglycaemia symptoms.
Contraindications
- Hypersensitivity to insulin aspart or any excipient
- Active hypoglycaemia; for compatible pen devices only — not for syringes
Pregnancy & Lactation
Pregnancy: Insulin aspart approved for pregnancy; specialist supervision required. Lactation: Not expected at clinically significant concentrations in breast milk.
Precautions & Warnings
- Compatible devices only: NovoPen 4, 5, Echo. Do not use with syringes or incompatible systems.
- Eat within 15 minutes of injection.
- Clear solution: Do not use if cloudy or discoloured.
- Prime device before first use of each new cartridge.
Overdose
Hypoglycaemia lasting 3–5 hours. Mild: oral glucose. Severe: IV dextrose or IM glucagon. Monitor until stable.
Storage Instructions
- Unopened: 2–8°C. Do not freeze. Protect from light.
- In-use (loaded pen): Below 30°C. Do not refrigerate.
- Discard 28 days after first use.
Frequently Asked Questions (FAQs)
Q1: What is the difference between NovoRapid Penfill and FlexPen?
Identical insulin aspart 100 IU/ml. FlexPen is pre-filled disposable. Penfill is a refill cartridge for NovoPen 4/5/Echo reusable devices. Penfill preferred for sustainability or NovoPen Echo dose memory feature.
Q2: Which pen devices are compatible with NovoRapid Penfill?
NovoPen 4, NovoPen 5, and NovoPen Echo. Confirm 3ml Penfill compatibility with your device manual.
Q3: Can NovoRapid Penfill be used in an insulin pump?
Yes — insulin aspart is approved for CSII pump therapy. Use pump-specific cartridges per pump manufacturer guidance.
Q4: Who manufactures NovoRapid Penfill?
Novo Nordisk A/S (Denmark).
⚕ Medical Disclaimer: For educational purposes only. NovoRapid Penfill is Rx-only. Consult your diabetologist before changing insulin therapy. DiabetesStore.com.bd is a licensed online pharmacy.
